It's IPO day for J&J's Kenvue: Stock gains 20% in first day of trading as unit raises $3.8B

Drew Armstrong

Executive Editor

Nicole DeFeudis

Editor

In one of the biggest healthcare IPOs of the last decade, Johnson & Johnson’s consumer spinout Kenvue raised $3.8 billion and started trading on the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

It's IPO day for J&J's Kenvue: Stock gains 20% in first day of trading as unit raises $3.8B

Drew Armstrong

Executive Editor

Nicole DeFeudis

Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA approves first drug to treat ultra-rare lipid storage disease

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

It's IPO day for J&J's Ken­vue: Stock gains 20% in first day of trad­ing as unit rais­es $3.8B

Executive Editor

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

It's IPO day for J&J's Kenvue: Stock gains 20% in first day of trading as unit raises $3.8B